0001558370-25-002912.txt : 20250313 0001558370-25-002912.hdr.sgml : 20250313 20250313170016 ACCESSION NUMBER: 0001558370-25-002912 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250311 ITEM INFORMATION: Changes in Registrant's Certifying Accountant ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250313 DATE AS OF CHANGE: 20250313 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ArriVent BioPharma, Inc. CENTRAL INDEX KEY: 0001868279 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41929 FILM NUMBER: 25736665 BUSINESS ADDRESS: STREET 1: 18 CAMPUS BLVD. STREET 2: SUITE 100 CITY: NEWTOWN SQUARE STATE: PA ZIP: 19073-3269 BUSINESS PHONE: 240-780-6356 MAIL ADDRESS: STREET 1: 18 CAMPUS BLVD. STREET 2: SUITE 100 CITY: NEWTOWN SQUARE STATE: PA ZIP: 19073-3269 FORMER COMPANY: FORMER CONFORMED NAME: ArriVent Biopharma, Inc. DATE OF NAME CHANGE: 20210617 8-K 1 avbp-20250311x8k.htm 8-K
0001868279false00018682792025-03-112025-03-11

​

 

​

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

FORM 8-K

​

CURRENT REPORT 

Pursuant to Section 13 or 15(d) 

of the Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): March 11, 2025

​

ARRIVENT BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

​

Delaware

 

001-41929

 

86-3336099

(State or other jurisdiction
of incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification No.)

​

​

​

18 Campus Boulevard, Suite 100

Newtown Square, PA

 

19073

(Address of principal executive offices)

 

(zip code)

​

Registrant’s telephone number, including area code: (628) 277-4836

​

N/A 

(Former name or former address, if changed since last report.)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

☐

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock, $0.0001 par value per share

 

AVBP

 

The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

​

Emerging Growth Company ☒

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

 

 

​

Item 4.01 Changes in the Registrant’s Certifying Accountant.

(a) Dismissal of Previous Independent Registered Public Accounting Firm

​

On March 11, 2025, the Audit Committee (the “Audit Committee”) of the Board of Directors of ArriVent BioPharma, Inc. (the “Company”) approved the dismissal of KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm. The dismissal was not related to any disagreements with KPMG on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure.

The reports of KPMG on the financial statements of the Company as of and for the fiscal years ended December 31, 2024 and 2023 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles.

During the fiscal years ended December 31, 2024 and 2023 and during the interim period through March 11, 2025, there were (a) no disagreements within the meaning of Item 304(a)(1)(iv) of Regulation S-K between the Company and KPMG on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, any of which, if not resolved to the satisfaction of KPMG, would have caused KPMG to make reference thereto in their reports, and (b) no “reportable events” within the meaning of Item 304(a)(1)(v) of Regulation S-K except for the material weaknesses in the Company’s internal control over financial reporting as previously reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 28, 2024 with respect to (i) the review and approval of manual journal entries and (ii) the accounting for certain nonroutine transactions. The material weakness with respect to the accounting for certain nonroutine transactions resulted in the restatement of the Company’s financial statements for the year ended December 31, 2022. These material weaknesses were remediated as of December 31, 2024, as previously reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025. These reportable events were discussed among the Audit Committee and KPMG. KPMG has been authorized by the Company to respond fully to the inquiries of PwC, the successor independent registered public accounting firm, concerning these reportable events.

The Company provided KPMG with a copy of the above disclosures and has requested that KPMG furnish the Company with a letter addressed to the SEC stating whether it agrees with the statements made herein and, if not, stating the respects in which it does not agree. A copy of KPMG’s letter dated March 13, 2025 is filed as Exhibit 16.1 to this Current Report on Form 8-K.

(b) Appointment of New Independent Registered Public Accounting Firm

On March 11, 2025, the Audit Committee appointed PricewaterhouseCoopers LLP (“PwC”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. During the Company’s two most recent fiscal years ended December 31, 2024 and 2023, and during the interim period through March 11, 2025, neither the Company nor anyone on its behalf has consulted with PwC regarding any of the matters described in Items 304(a)(2)(i) and (ii) of Regulation S-K.

​

​

​

​

Item 9.01Financial Statements and Exhibits.

(d) Exhibits.

​

​

Exhibit

No.

 

Description

16.1

 

Letter from KPMG LLP, dated March 13, 2025.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

​

​

​

​

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

ARRIVENT BIOPHARMA, INC.

 

 

 

 

By:

/s/ Winston Kung

 

 

Winston Kung

 

 

Chief Financial Officer and Treasurer

​

 

Date: March 13, 2025

​

​

​

 EX-16.1 2 avbp-20250311xex16d1.htm EX-16.1 Inquiry Express: US-25-03-45285

‌Exhibit 16.1

​

March 13, 2025

Securities and Exchange Commission
Washington, D.C. 20549

Ladies and Gentlemen:

We were previously principal accountants for ArriVent BioPharma, Inc. (the Company) and, under the date of March 3, 2025, we reported on the financial statements of the Company as of and for the years ended December 31, 2024 and 2023. On March 11, 2025, we were dismissed.

We have read the Company’s statements included under Item 4.01 of its Form 8-K dated March 13, 2025, and we agree with such statements, except that we are not in a position to agree or disagree with the Company’s stated reason for changing principal accountants, that the change was approved by the Company’s Audit Committee of the Board of Directors and the statements in item 4.01(b).

Very truly yours,

/s/ KPMG LLP

​

 EX-101.SCH 3 avbp-20250311.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 avbp-20250311_lab.xml EX-101.LAB EX-101.PRE 5 avbp-20250311_pre.xml EX-101.PRE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.25.0.1
Document and Entity Information
Mar. 11, 2025
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Mar. 11, 2025
Entity Registrant Name ARRIVENT BIOPHARMA, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-41929
Entity Tax Identification Number 86-3336099
Entity Address, Address Line One 18 Campus Boulevard
Entity Address, Adress Line Two Suite 100
Entity Address, City or Town Newtown Square
Entity Address State Or Province PA
Entity Address, Postal Zip Code 19073
City Area Code 628
Local Phone Number 277-4836
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol AVBP
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001868279
Amendment Flag false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.0.1 html 1 24 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://arrivent.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports avbp-20250311.xsd avbp-20250311_lab.xml avbp-20250311_pre.xml avbp-20250311x8k.htm http://xbrl.sec.gov/dei/2024 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "avbp-20250311x8k.htm": { "nsprefix": "avbp", "nsuri": "http://arrivent.com/20250311", "dts": { "schema": { "local": [ "avbp-20250311.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd" ] }, "labelLink": { "local": [ "avbp-20250311_lab.xml" ] }, "presentationLink": { "local": [ "avbp-20250311_pre.xml" ] }, "inline": { "local": [ "avbp-20250311x8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 24 }, "report": { "R1": { "role": "http://arrivent.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_3_11_2025_To_3_11_2025_XBf4MFa4y0WsysNGgPbMYQ", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "avbp-20250311x8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_3_11_2025_To_3_11_2025_XBf4MFa4y0WsysNGgPbMYQ", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "avbp-20250311x8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://arrivent.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://arrivent.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://arrivent.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://arrivent.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://arrivent.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://arrivent.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Adress Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://arrivent.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://arrivent.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://arrivent.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://arrivent.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://arrivent.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://arrivent.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://arrivent.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://arrivent.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://arrivent.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://arrivent.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://arrivent.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://arrivent.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://arrivent.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://arrivent.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://arrivent.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://arrivent.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://arrivent.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://arrivent.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001558370-25-002912-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-25-002912-xbrl.zip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end XML 16 avbp-20250311x8k_htm.xml IDEA: XBRL DOCUMENT 0001868279 2025-03-11 2025-03-11 0001868279 false 8-K 2025-03-11 ARRIVENT BIOPHARMA, INC. DE 001-41929 86-3336099 18 Campus Boulevard Suite 100 Newtown Square PA 19073 628 277-4836 false false false false Common Stock, $0.0001 par value per share AVBP NASDAQ true false